low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, financing environment for unprofitable biotech is highly sensitive to risk appetite, which correlates with economic conditions. During recessions, venture capital and public market funding for clinical-stage companies contracts significantly, creating existential risk for cash-burning entities.

High sensitivity through multiple channels: (1) Valuation - biotech DCF models heavily weight distant cash flows, making them extremely sensitive to discount rates. Rising rates compress NPV of pipeline assets. (2) Financing costs - while current 0.34x debt/equity is modest, future capital raises become more expensive in high-rate environments. (3) Opportunity cost - investors rotate from speculative growth to safer yield alternatives when risk-free rates rise. (4) Cash management - higher rates provide better returns on $155M+ cash balance (implied from 7.87x current ratio).

growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from successful clinical development. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail speculators. Not suitable for value or income investors given negative earnings, no dividends, and binary clinical outcomes. Recent 37% 3-month rally suggests momentum traders are active, likely driven by sector rotation or specific catalyst anticipation.